XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 8 - Supplemental Equity and Accumulated Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Dec. 31, 2020

Notes Tables

Schedule of Stockholders Equity [Table Text Block]

		Bio-Techne Shareholders
																		Accumulated
										Additional								Other
		Common Stock								Paid-in				Retained				Comprehensive				Noncontrolling
		Shares				Amount				Capital				Earnings				Income(Loss)				Interest				Total
Balances at June 30, 2020			38,453			$	385			$	420,536			$	1,057,470			$	(97,199	)		$	-			$	1,381,192
Cumulative effect adjustments due to adoption of new accounting standards															(276	)											(276	)
Net earnings															33,395												33,395
Other comprehensive income																			14,057								14,057
Common stock issued for exercise of options			117				1				13,727																13,728
Common stock issued for restricted stock awards			25				0				(0	)			(4,890	)											(4,890	)
Cash dividends															(12,336	)											(12,336	)
Stock-based compensation expense											12,667																12,667
Common stock issued to employee stock purchase plan			6				0				1,463																1,463
Employee stock purchase plan expense											286																286
Balances at September 30, 2020			38,601			$	386			$	448,679			$	1,073,362			$	(83,142	)		$	-			$	1,439,285
Non-controlling interest in Eminence																							8,985				8,985
Net earnings															46,274								(130	)			46,144
Other comprehensive income																			18,904				83				18,987
Common stock issued for exercise of options			161				2				16,748				(2,482	)											14,268
Common stock issued for restricted stock awards			3				0				(0	)			0												0
Cash dividends															(12,392	)											(12,392	)
Stock-based compensation expense											15,471																15,471
Employee stock purchase plan expense											106																106
Balances at December 31, 2020			38,765			$	388			$	481,004			$	1,104,762			$	(64,238	)		$	8,938			$	1,530,854

																		Accumulated
										Additional								Other
		Common Stock								Paid-in				Retained				Comprehensive
		Shares				Amount				Capital				Earnings				Income(Loss)				Total
Balances at June 30, 2019			37,934			$	379			$	316,797			$	931,934			$	(83,521	)		$	1,165,589
Cumulative effect adjustments due to adoption of new accounting standards and other															(879	)							(879	)
Net earnings															14,398								14,398
Other comprehensive loss																			(8,106	)			(8,106	)
Common stock issued for exercise of options			94				1				7,854												7,855
Common stock issued for restricted stock awards			50				0				(0	)			(1,926	)							(1,926	)
Cash dividends															(12,169	)							(12,169	)
Stock-based compensation expense											8,267												8,267
Common stock issued to employee stock purchase plan			6				0				1,096												1,096
Employee stock purchase plan expense											99												99
Balances at September 30, 2019			38,084			$	381			$	334,112			$	931,358			$	(91,627	)		$	1,174,224
Net earnings															119,622								119,622
Other comprehensive loss																			13,275				13,275
Common stock issued for exercise of options			195				2				18,293												18,295
Common stock issued for restricted stock awards			4				0				(0	)											0
Cash dividends															(12,197	)							(12,197	)
Stock-based compensation expense											10,017												10,017
Common stock issued to employee stock purchase plan																							0
Employee stock purchase plan expense											112												112
Balances at December 31, 2019			38,283			$	383			$	362,534			$	1,038,783			$	(78,352	)		$	1,323,348

Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]

		Unrealized Gains (Losses) on Derivative Instruments				Foreign Currency Translation Adjustments				Total
Balance as of June 30, 2020 attributable to Bio-Techne		$	(13,253	)		$	(83,946	)		$	(97,199	)
Other comprehensive income (loss) before reclassifications, net of taxes, attributable to Bio-Techne			(47)				28,759				28,712
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽¹⁾			4,249				-				4,249
Balance as of December 31, 2020 attributable to Bio-Techne⁽³⁾		$	(9,051	)		$	(55,187	)		$	(64,238	)

		Unrealized Gains (Losses) on Derivative Instruments				Foreign Currency Translation Adjustments				Total
Balance as of June 30, 2019 attributable to Bio-Techne		$	(9,537	)		$	(73,983	)		$	(83,521	)
Other comprehensive income (loss), net of tax before reclassifications, attributable to Bio-Techne			275				4,264				4,539
Reclassification from loss on derivatives to interest expense, net of taxes, attributable to Bio-Techne⁽²⁾			629				-				629
Balance as of December 31, 2019 attributable to Bio-Techne⁽³⁾		$	(8,633	)		$	(69,719	)		$	(78,352	)